Oncotarget Journal

Attending the American Association for Cancer Research (AACR) Annual Meeting? Come meet members of the Impact Journals team at Booth 3641. Explore #research publications and discuss opportunities for collaboration and #manuscript submissions. #Cancer #AACR26 #AnnualMeeting

🔬 Scientific integrity is at the core of scholarly publishing. A new editorial from Oncotarget highlights publishing industry trends, measurable journal comparisons, and future strategy. 🔗 doi.org/10.18632/oncot… #ScientificIntegrity #AcademicPublishing #OA #Research

📈 #TrendingWithImpact: This #research paper was #published in Volume 17, titled "Epigenetic dysregulation and biological function of PDX1 in prostate cancer." #PressRelease ⬇️ oncotarget.net/2026/04/15/epi… #cancer #prostatecancer #DNAMethylation #press #oa #peerreview #publishing

@Thatsregrettab1 We responded in detail to your questions written using an LLM. You criticize others using an LLM. Why don't you follow the rules? Please ask your colleagues what selective targeting is. Regarding the 2019 post, please read our Editorial. This concludes our communication.

@OncotargetJrnl It doesn’t take a rocket scientist to see problems with the references. Someone just has to care. “Its oncology hubs now extend to East Africa and conflict-affected regions in the Middle East [64, 65].” Brazil is not in East Africa or the Middle East.

New Oncotarget paper seems to have some problematic references... possibly due to LLM use. Don't they check for that? pubpeer.com/publications/7…

@Thatsregrettab1 The best response is to present numbers and scientific explanations, instead of constant communication on X. That is why we will continue to publish editorials on different topics in the publishing industry, including selective targeting.

@Thatsregrettab1 You use non-professional language and your posts reflect the disproportionate coverage of Oncotarget compared to other journals with greater integrity concerns. This is selective targeting, which is why you're blocked.

🔆 #PaperSpotlight: This #review was #published in Volume 17, titled "Cancer without borders: Policy frameworks for oncology care in humanitarian and conflict settings." #PressRelease ⬇️ oncotarget.net/2026/04/13/can… #cancer #research #healthcare #oncology #press #oa #peerreviewed

🔆 #PaperSpotlight: This #editorial perspective from Volume 17 explores "Oncotarget: Past, Present and Future: Trends in the publishing industry." #PressRelease ⬇️ oncotarget.net/2026/04/10/onc… #publishing #research #integrity #oncology #science #perspective #openaccess

@Thatsregrettab1 Please see page 175, first paragraph.

They missed this one. It should be retracted and was published in 2020. pubpeer.com/publications/1…

🔬 Scientific integrity is at the core of scholarly publishing. A new editorial from Oncotarget highlights publishing industry trends, measurable journal comparisons, and future strategy. 🔗 doi.org/10.18632/oncot… #ScientificIntegrity #AcademicPublishing #OA #Research

📈 #TrendingWithImpact: "Efficacy and safety of PD-1/ PD-L1 inhibitors as adjuvants in the treatment of patients with solid cancers: A systematic review and meta-analysis of randomized controlled trials" #PressRelease ⬇️ oncotarget.net/2026/04/07/adj… #cancer #research #oa #publishing

🔆 #PaperSpotlight: This #review was #published in Volume 17, titled "Bibliometric mapping of glioma classification research through main path, key route, and K-core analyses." #PressRelease ⬇️ oncotarget.net/2026/04/06/bib… #cancer #glioma #press #publishing #oa #peerreview #journal

📈 #TrendingWithImpact: This #research paper was #published in Volume 17, titled "The SCD1 inhibitor aramchol interacts with regorafenib and metformin to kill tumor cells." #PressRelease ⬇️ oncotarget.net/2026/03/31/the… #cancer #press #metformin #melanoma #oa #publishing #meded

🔆 #PaperSpotlight: This #research paper was #published in Volume 17, titled "CREB5 regulates stem cell-like transcriptional programs to enhance tumor progression in prostate cancer." #PressRelease ⬇️ oncotarget.net/2026/03/24/cre… #cancer #prostatecancer #publishing #oa #press

Impact Journals (publisher of Oncotarget) is a proud #exhibitor at the upcoming @AACR Annual Meeting 2026, taking place April 17–22 at the San Diego Convention Center. Be sure to stop by Booth 3641 to meet members of the team. #Cancer #AACR26 #AnnualMeeting #Conference

📈 #TrendingWithImpact: This #editorial perspective was #published in Volume 17, titled "CAR-T therapy: Trailblazing CAR(ing) in cancer treatment." #PressRelease ⬇️ oncotarget.net/2026/02/25/nex… #cancer #press #Tcells #cancertherapy #perspective #oa #peerreview #journal #publishing

📈 #TrendingWithImpact: "Exploring the potential link between mRNA COVID-19 vaccinations and cancer: A case report with a review of haematopoietic malignancies with insights into pathogenic mechanisms" #PressRelease ⬇️ oncotarget.net/2026/02/11/cas… #cancer #COVID19 #oa #publishing

When Censorship of Science Sparks a Firestorm: A COVID-Vaccine–Cancer Review and the Backlash That Followed A review authored by Tufts and Brown researchers Dr. Charlotte Kuperwasser (@KUPERWASSERLAB) and Dr. Wafik S. El-Deiry (@weldeiry) and published in @Oncotarget examines the temporal relationship between COVID-19 vaccination and cancer. IMA Chief Scientific Officer @drpaulmarik1 breaks down the paper’s key findings, the cyberattack on the journal that followed, and how early suppression of the article ultimately amplified global awareness of its findings.

🔆 #PaperSpotlight: This #hypothesis was #published in Volume 17, titled "Hypothesis: HPV E6 and COVID spike proteins cooperate in targeting tumor suppression by p53." #PressRelease ⬇️ oncotarget.com/news/pr/new-hy… #cancer #COVID #HPV #p53 #press #oa #peerreview #publishing #meded